Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS)

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Atrial fibrillation1 trial
• Glioblastoma1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Stroke1 trial

Phase

• Phase 33 trials

Status

• Active, not recruiting2 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• NovoCure GmbH2 trials
• European Myeloma Network B.V.1 trial
• Hamilton Health Sciences Corporation1 trial

Running trials

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

  Contact: Charles Dussault, MD (principal investigator)

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

  NCT02973789· Phase 3· NovoCure GmbH· Source